ICHNO-ECHNO 2022 - Abstract Book

S117

ICHNO-ECHNO 2022

PO-0185 Tolerance of Radical Radiotherapy Among Elderly Head and Neck Cancer Patients

I. Madabhavi 1 , S. K S 2 , S. Revannasiddaiah 3 , M. Sarkar 4 , R. Sagar 5

1 Kerudi Cancer Hospital, Bagalkot, J N Medical College, Belagavi, and Nanjappa Hospital, Shimoga, Karnataka, India. , Department of Medical and Pediatric Oncology,, Bagalkot, India; 2 Shankar Hospital and Research Centre, Dertment of Medical Oncology, Bangalore, India; 3 M S R Medical College, Department of Medical Oncology, Bangalore, India; 4 I G M C shimla, Department of Pulmonary Medicine., Shimla, India; 5 J N Medical College, Belagavi,, Department of Radiation Oncology., Belagavi, India Purpose or Objective Head and neck cancers usually occur in the elderly age group and about half of the cases occur at the age > 60 years with majority detected in an advanced stage with increased morbidity and decreasing compliance to therapy. Since there are limited data available for the adequate treatment of elderly head and neck cancer patients, we proposed a study to analyze tolerance and response based on age, site, modality of treatment received, and implication of nutrition vs weight loss during treatment. Materials and Methods Fifty five patients were enrolled in this study, which was conducted between November 2015 and April 2017, and those who met the eligibility criteria were evaluated with a detailed history and physical examination, and biochemical, pathological, and radio logical investigations. Patients were staged based on TNM staging and treated as per the standard guidelines. Patients were assessed with the weekly routine blood investigation, weight loss, and toxicity. Results The response was assessed after 6 weeks and documented as per RECIST criteria. 52/55 (94.5%) patients completed the treatment, and 48/55 (92.3%) had a complete response at 6 weeks (p value 0.000) with a mean treatment duration of 46.67 days and mean weight loss of 5.44 kg with 55.4% having GR-II mucositis, 40% having GRIII mucositis at the time of completion of treatment. Sixty-eight percent having GRII and 38.2% having GR I dermatitis and 80% had moderate pain. Subgroup analysis was done based on age, site, and treatment modality. Patients were also assessed for nutrition vs weight loss. Conclusion We concluded that elderly patients tolerate and respond well to radical treatment with acceptable toxicities; hence, age should not be a barrier to decide treatment. P. Guillén Sentís 1 , C. Castillo 1 , S. Tous 2,9 , M. Plana 1 , A. Lozano 3 , J. Brenes 1 , C. Erasun 1 , I. Linares 3 , G. Cefarelli 1 , M. Labori 4 , M. Gomà 5 , J. Tornero 6 , M. Melero 7 , O. Bermejo 8 , L. Alemany 2,9 , R. Mesía 1 , M.E. Vilajosana 1 , V. Gómez 1 , M. Oliva 1 , F. Morey 2 , B. Quirós 2,9 1 Institut Català d'Oncologia, Medical Oncology, Hospitalet de Llobregat, Spain; 2 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL-ICO), Cancer Epidemiology Research Program, Hospitalet de Llobregat, Spain; 3 Institut Català d'Oncologia, Radiation Oncology, Hospitalet de Llobregat, Spain; 4 Institut Català d'Oncologia, Palliative Care Unit, Hospitalet de Llobregat, Spain; 5 Hospital Universitari de Bellvitge, Anatomic Pathology, Hospitalet de Llobregat, Spain; 6 Hospital Universitari de Bellvitge, Otorhinolaryngology, Hospitalet de Llobregat, Spain; 7 Hospital Universitari de Bellvitge, Oral and Maxillofacial Surgery, Hospitalet de Llobregat, Spain; 8 Hospital Universitari de Bellvitge, Plastic Surgery, Hospitalet de Llobregat, Spain; 9 Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Madrid, Spain Purpose or Objective Management of cancer patients (pts) was compromised during COVID19 pandemic. Our group previously evaluated the impact of COVID19 on treatment outcome of HNC pts ( Guillen P. et al, ASCO 2021, Abs.6061 ). Here we present the results of a prospective patient-based evaluation of the impediments to access HNC diagnosis after the second COVID19 wave. Materials and Methods A single institution cohort of newly-diagnosed HNC pts consecutively visited at HNC Functional Unit at ICO between Dec2020- Jun2021 was asked to answer a 6-items survey at the first HNC specialist consultation ( Figure 1 ) . Cohort characteristics were collected from our in-site prospective database. Descriptive statistics were used to summarize data obtained from survey. Patient and disease characteristics were compared according to the nº of medical consults (MC) before being referred to an HNC specialist (MC<3 versus ≥ 3) and median time between first symptom and first MC using Chi-2 and Student's t-test. Poster: COVID-19 PO-0186 Impact of COVID19 on the diagnosis of head and neck cancer (IMPACCT Study).